Navigation Links
MacuLogix Raises $3.6 Million in Series A Round
Date:3/11/2013

HUMMELSTOWN, Pa., March 11, 2013 /PRNewswire/ -- MacuLogix, Inc., a pioneer in the early detection and tracking of age-related macular degeneration (AMD), today announced it has raised $3.6 million in Series A funding. Investors include Berwind Private Equity, Roche Venture Fund, Life Sciences Greenhouse of Central Pennsylvania, and Ben Franklin Technology Partners of Central and Northern Pennsylvania.

The funds will be used to accelerate manufacturing and commercial sales of the MacuLogix' AdaptDx™. The AdaptDx™ is being developed to be the first practical diagnostic for early detection and tracking of AMD. Based on significant advances in the measurement of dark adaptation, the AdaptDx™ will provide doctors with an easy-to-use, functional diagnostic similar to routine perimetry testing for glaucoma. With this important new tool, doctors will be able to intervene at the earliest possible time to prevent vision loss and improve quality of life.

"MacuLogix represents a favorable investment opportunity as it addresses a large and growing market for AMD which is the leading cause of adult vision loss and blindness in developed countries," said A. Laurence Norton , Managing Director of Berwind Private Equity. "We understand the AdaptDx™ has the potential to fundamentally transform the way eye doctors detect and manage AMD for millions of people worldwide."

"Closing our Series A round is a very significant achievement for the company," said John G. Edwards , CEO of MacuLogix. "We have completed numerous clinical studies involving more than 1,000 patients with additional studies ongoing, all at major research centers such as Harvard University, the National Eye Institute and University of Alabama at Birmingham. This financing allows us to take the next step."

About MacuLogix
MacuLogix is a pioneer in the early detection and tracking of age-related macular degeneration (AMD). MacuLogix' AdaptDx™ has received FDA 510(k) clearance for measurement of dark adaptation function and patient testing has been completed to support validation as a diagnostic for AMD. However, the AdaptDx™ is not currently cleared for sale as a diagnostic. In addition, the AdaptDx™ is being used by a number of pharmaceutical companies in the development of drugs for early AMD. 

For more information, visit www.maculogix.com


'/>"/>
SOURCE MacuLogix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Evergreen Healthcare Foundation Gala Raises Nearly $1.1 Million to Benefit Breast Health Center
2. Xtelligent Media Raises $800K in Funding and Launches EHRintelligence.com
3. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
4. BHI Raises Awareness of Hearing Aids as Potential Therapy to Help Quiet "Ringing in the Ears" During National Tinnitus Awareness Week
5. Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance
6. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
7. Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100
8. AssureRx Health Raises $12.5 Million Series C Financing
9. InnoPharma Inc. Raises $8 Million in Venture Debt
10. Lilly Reports Second-Quarter 2012 Results, Raises 2012 EPS Guidance
11. Retia Medical Raises $7 Million to Develop Accurate, Less-Invasive Cardiovascular Monitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Allergy Diagnostics Market: Scope and Methodology ... are used to determine the presence of allergens ... etc. in the samples by determining the presence ... report on global allergy diagnostics market, analyzes the ... report consists of an executive summary that provides ...
(Date:12/8/2016)... Mass. , Dec. 8, 2016   ... that Nationwide Children,s Hospital signed a ... and accelerate the development of new cures. ... organizations representing over 57 million patients globally, biopharmaceutical ... working together to improve protocol design, site selection, ...
(Date:12/8/2016)... True Health Diagnostics today announced a ... and management expertise to hospital systems throughout ... doctors and patients to benefit from state-of-the-art biomarker ... Logo - http://photos.prnewswire.com/prnh/20161208/447162LOGO ... to contain costs, have struggled to keep up ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 08, 2016 , ... After enjoying record-breaking attendance at its ... its 33rd Annual Issues & Research Conference, March 2-3, 2017, at the ... conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation ... adherence, and other pharmacist-delivered patient care services, has announced the promotions of Karen ... to vice president of sales. , Litsinger joined Mirixa in 2008 after ...
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and The Chopra Center ... loss and wellness program, at their world headquarters of Omni La Costa Resort & ... results to anyone seeking weight loss, personal development, a healthy lifestyle, or mental and ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... has been recognized for adherence to the highest standards of trauma, maternity, cancer ... announced the center's president and CEO, Dr. Daniel Messina. , Among the recognitions, ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Care Act. Dr. Botelho advocates for the mass media launching of story movements ... ongoing opportunities to share their unfortunate experiences; such a movement can generate the ...
Breaking Medicine News(10 mins):